Search

Your search keyword '"de Ru A"' showing total 1,515 results

Search Constraints

Start Over You searched for: Author "de Ru A" Remove constraint Author: "de Ru A"
1,515 results on '"de Ru A"'

Search Results

51. A library of cancer testis specific T cell receptors for T cell receptor gene therapy

55. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia

58. Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry

60. Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma

61. Supplementary Methods S1 from Neoantigen Targetability in Progressive Advanced Melanoma

62. Supplementary Figure S3 from Neoantigen Targetability in Progressive Advanced Melanoma

63. Data from Neoantigen Targetability in Progressive Advanced Melanoma

64. Neoantigen Targetability in Progressive Advanced Melanoma

65. Cellular Validation of a Chemically Improved Inhibitor Identifies Monoubiquitination on OTUB2

66. CD44 acts as a coreceptor for cell-specific enhancement of signaling and regulatory T cell induction by TGM1, a parasite TGF-β mimic

68. SUMO-activated target traps (SATTs) enable the identification of a comprehensive E3-specific SUMO proteome

71. An exploratory study on the presence of sensory nerves in the caudal part of the trapezius

76. Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis

77. This title is unavailable for guests, please login to see more information.

78. SUMO-activated Target Traps (SATTs) Enable the Identification of a Comprehensive E3-specific SUMO Proteome

79. Supplementary Table 3 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

80. Supplementary Figure 2 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

81. Supplementary Table 2 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

82. Supplementary Table 1 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

83. Supplementary Figures 1-3 from PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

84. Supplementary Methods, Figure Legends 1-3 from PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

85. Supplementary Figure 1 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

86. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer

88. ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation

89. Cutting Edge: Unconventional CD8+ T Cell Recognition of a Naturally Occurring HLA-A*02:01–Restricted 20mer Epitope

90. Data from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

91. Data from PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

92. Supplementary Table 3 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

93. Supplementary Table 2 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

94. Supplementary Figures 1-3 from PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

95. Supplementary Figure 2 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

96. Supplementary Methods, Figure Legends 1-3 from PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

97. Supplementary Table 1 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

98. Supplementary Figure 1 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach

Catalog

Books, media, physical & digital resources